IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection-Reference-Cited by-同舟云学术

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

Published:2006 Issue:6 Volume:44 Page:1617-1625
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Lagging Martin,Romero Ana I.,Westin Johan,Norkrans Gunnar,Dhillon Amar P.,Pawlotsky Jean-Michel,Zeuzem Stefan,von Wagner Michael,Negro Francesco,Schalm Solko W.,Haagmans Bart L.,Ferrari Carlo,Missale Gabriele,Neumann Avidan U.,Verheij-Hart Elke,Hellstrand Kristoffer,

Publisher

Wiley

Subject

Hepatology

Reference21 articles.

1. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2. Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C

3. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

4. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C

5. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum inducible protein 10 kDa/C‐X‐C motif chemokine 10 levels predict regression of M2BPGi‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents;Hepatology Research;2023-09-06

2. The CXCL9/10/11-CXCR3 axis as a predictor of COVID-19 progression: a prospective, case-control study;Revista da Sociedade Brasileira de Medicina Tropical;2023

3. Significance of serum IP‐10/CXCL10 measurement in predicting post‐direct acting antiviral treatment liver function in patients with HCV‐decompensated liver cirrhosis;Hepatology Research;2022-12-13

4. CXCL10 Chemokine: A Critical Player in RNA and DNA Viral Infections;Viruses;2022-11-03

5. IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection;Frontiers in Public Health;2022-07-18